JP2005500831A5 - - Google Patents

Download PDF

Info

Publication number
JP2005500831A5
JP2005500831A5 JP2003505346A JP2003505346A JP2005500831A5 JP 2005500831 A5 JP2005500831 A5 JP 2005500831A5 JP 2003505346 A JP2003505346 A JP 2003505346A JP 2003505346 A JP2003505346 A JP 2003505346A JP 2005500831 A5 JP2005500831 A5 JP 2005500831A5
Authority
JP
Japan
Prior art keywords
factor viii
variant
polypeptide
nucleic acid
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003505346A
Other languages
English (en)
Japanese (ja)
Other versions
JP4361786B2 (ja
JP2005500831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/019017 external-priority patent/WO2002103024A2/en
Publication of JP2005500831A publication Critical patent/JP2005500831A/ja
Publication of JP2005500831A5 publication Critical patent/JP2005500831A5/ja
Application granted granted Critical
Publication of JP4361786B2 publication Critical patent/JP4361786B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003505346A 2001-06-14 2002-06-14 操作されたジスルフィド結合を有する安定化蛋白質 Expired - Fee Related JP4361786B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29857801P 2001-06-14 2001-06-14
PCT/US2002/019017 WO2002103024A2 (en) 2001-06-14 2002-06-14 Stabilized proteins with engineered disulfide bonds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008124202A Division JP2008271975A (ja) 2001-06-14 2008-05-12 操作されたジスルフィド結合を有する安定化蛋白質

Publications (3)

Publication Number Publication Date
JP2005500831A JP2005500831A (ja) 2005-01-13
JP2005500831A5 true JP2005500831A5 (cg-RX-API-DMAC7.html) 2006-01-05
JP4361786B2 JP4361786B2 (ja) 2009-11-11

Family

ID=23151124

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003505346A Expired - Fee Related JP4361786B2 (ja) 2001-06-14 2002-06-14 操作されたジスルフィド結合を有する安定化蛋白質
JP2008124202A Pending JP2008271975A (ja) 2001-06-14 2008-05-12 操作されたジスルフィド結合を有する安定化蛋白質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008124202A Pending JP2008271975A (ja) 2001-06-14 2008-05-12 操作されたジスルフィド結合を有する安定化蛋白質

Country Status (8)

Country Link
US (2) US7205278B2 (cg-RX-API-DMAC7.html)
EP (2) EP1421539B1 (cg-RX-API-DMAC7.html)
JP (2) JP4361786B2 (cg-RX-API-DMAC7.html)
AU (1) AU2002310438B2 (cg-RX-API-DMAC7.html)
CA (1) CA2450732A1 (cg-RX-API-DMAC7.html)
DE (1) DE60234193D1 (cg-RX-API-DMAC7.html)
ES (1) ES2331909T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002103024A2 (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421539B1 (en) * 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds
EP1502921A1 (en) * 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
ATE463572T1 (de) * 2003-12-03 2010-04-15 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
US20060019893A1 (en) * 2004-07-02 2006-01-26 Genentech, Inc. Factor VIIa variants
DK2371856T3 (en) 2004-11-12 2022-08-08 Bayer Healthcare Llc Site-directed modifikation af FVIII
KR20080007226A (ko) * 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2008059041A2 (en) * 2006-11-16 2008-05-22 Crucell Holland B.V. Complementation of factor xi deficiency by factor v mutants
WO2008077616A1 (en) 2006-12-22 2008-07-03 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
CA2703948A1 (en) * 2007-11-01 2009-05-07 University Of Rochester Recombinant factor viii having increased stability
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
JP5816097B2 (ja) * 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
JP5934101B2 (ja) * 2009-10-30 2016-06-15 アグリサーチ リミテッド 修飾された中性脂質を被包するタンパク質及びその使用
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー/エス 安定化させた第viii因子バリアント
CN103269720A (zh) * 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
US9458223B2 (en) 2012-02-15 2016-10-04 Csl Behring Gmbh Von willebrand factor variants having improved factor VIII binding affinity
US9238676B2 (en) 2012-05-17 2016-01-19 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
AU2014237111B2 (en) * 2013-03-15 2018-06-21 Bayer Healthcare Llc Recombinant factor VIII formulations
ES2841123T3 (es) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Formulación del compuesto de la hormona de crecimiento
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
EP3065768B1 (en) * 2013-11-04 2020-09-23 The Regents of the University of California Composition for use in treatment or prevention of conditions associated with bleeding or hypocoagulationcompostion
DK3164150T3 (da) 2014-07-02 2021-02-08 CSL Behring Lengnau AG Modificeret von willebrand-faktor
SG11201706659WA (en) 2015-03-06 2017-09-28 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CN104974228B (zh) * 2015-06-15 2017-10-17 四川合泰新光生物科技有限公司 一种小分子多肽zy4及其应用
SG11201805494WA (en) 2016-01-07 2018-07-30 Csl Behring Recombinant Facility Ag Mutated von willebrand factor
AU2017204955B2 (en) 2016-01-07 2021-04-01 CSL Behring Lengnau AG Mutated truncated von Willebrand Factor
DK3538133T3 (da) 2016-11-11 2021-04-19 CSL Behring Lengnau AG Trunkeret von willebrand faktor polypeptider til behandling af hæmofili
JP2020504082A (ja) 2016-11-11 2020-02-06 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド
WO2019203645A1 (en) 2018-04-19 2019-10-24 Stichting Vu Protein macrocyclization
US20210093735A1 (en) * 2018-04-26 2021-04-01 The University Of North Carolina At Chapel Hill Methods and compositions for treatment of hemophilia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214033A (en) 1983-03-31 1993-05-25 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
SE8501050D0 (sv) 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
MX9203440A (es) 1985-04-12 1992-07-01 Genetics Inst Proteinas procoagulantes novedosas.
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US5449759A (en) * 1987-05-16 1995-09-12 Somatogen, Inc. Hemoglobins with intersubunit desulfide bonds
US5827821A (en) * 1987-12-10 1998-10-27 The Burnham Institute Conformationally stabilized cell adhesion peptides
US5009889A (en) 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
US4852871A (en) * 1988-12-02 1989-08-01 John Perko Hand exercise device
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US5610137A (en) 1990-12-20 1997-03-11 The Uab Research Foundation Transgenic, cross-linked hemoglobin
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5114148A (en) * 1991-07-09 1992-05-19 Liu Ming Zen Puzzle device
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6180371B1 (en) 1996-06-26 2001-01-30 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5453937A (en) 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE4418635C2 (de) * 1994-05-27 1997-07-24 Immuno Ag Pharmazeutische Zusammensetzung zur Vorbeugung und Behandlung von Blutgerinnungsstörungen
US5681746A (en) * 1994-12-30 1997-10-28 Chiron Viagene, Inc. Retroviral delivery of full length factor VIII
US5543149A (en) * 1995-03-01 1996-08-06 Rubin; Stan M. Treatment for insect bites
US5935568A (en) 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5910481A (en) * 1995-11-13 1999-06-08 Immuno Ag Hybrid proteins with modified activity
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6262238B1 (en) * 1997-01-14 2001-07-17 Roche Diagnostic, Gmbh Process for modifying the stability of antibodies
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
EP1421539B1 (en) * 2001-06-14 2009-10-28 The Scripps Research Institute Stabilized factor viii with engineered disulfide bonds

Similar Documents

Publication Publication Date Title
Sadler Thrombomodulin structure and function
JP2655752B2 (ja) 組換えヒト第▲viii▼因子誘導体
Ribes et al. Fibrin induces release of von Willebrand factor from endothelial cells.
US7928199B2 (en) Stabilized proteins with engineered disulfide bonds
NO20024475D0 (no) Produksjon av rekombinante blodkoagulasjonsfaktorer i humane cellelinjer
JP2003530093A5 (cg-RX-API-DMAC7.html)
US20120164111A1 (en) Novel post-translational fibrinogen variants
EP1124846A4 (en) NUCLEOTID AND PROTEIN SEQUENCES OF NOGO GENES AND METHODS BASED ON THEM
JP2003530070A5 (cg-RX-API-DMAC7.html)
JPH05502161A (ja) 組換えヒト8因子誘導体
RU2007105677A (ru) Модифицированные витамин к-зависимые полипептиды
Wada et al. A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg--> Cys) in two unrelated kindred, Dusart and Chapel Hill III
JP2005538932A5 (cg-RX-API-DMAC7.html)
JP2549224B2 (ja) 組換えにより産生される血液因子及びその血液因子の発現方法並びにその方法に使用されるワクシニアウイルス組換え体
US5262309A (en) Terminal modifications of tumor necrosis factor
JP2004534503A5 (cg-RX-API-DMAC7.html)
CN114901686A (zh) 因子viii多肽
NO20013608L (no) DNA-klon for human vevsfaktorinhibitor
SK130696A3 (en) Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
ES2235153T3 (es) Dominios terapeuticos del factor de von willebrand.
JPH11507542A (ja) プロトロンビン誘導体
Lawn How often has Lp (a) evolved?
Gohda et al. Human hepatocyte growth factor in blood of patients with fulminant hepatic failure: basic aspects
Black Drug products of recombinant DNA technology
WO2011011841A1 (en) Human blood coagulation factor ix recombinant protein, composition, use of a factor ix recombinant protein, use of a composition, method of obtaining human blood coagulation factor ix recombinant protein and use of the factor ix recombinant protein